Literature DB >> 368440

Severe infection due to Streptococcus pneumoniae in asplenic renal transplant patients.

A M Bourgault, R E Van Scoy, C J Wilkowske, S Sterioff.   

Abstract

The medical records of 293 patients who underwent renal transplantation were analyzed for the occurrence of Streptococcus pneumoniae and Haemophilus influenzae infections in relation to splenectomy. Splenectomy was done in 236 (81%) graft recipients before or concomitant with transplantation. Bacteremia developed in five and fulminant sepsis in two from 3 to 32 months after splenectomy. No serious infections with these organisms occurred in the nonsplenectomy group. These results suggest that asplenia may be an additional factor predisposing transplant patients to serious infection. Prevention of these serious pneumococcal infections may be possible with polyvalent pneumococcal vaccine.

Entities:  

Mesh:

Year:  1979        PMID: 368440

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  4 in total

1.  Splenic autotransplant and residual partial spleen: prevention of septicemia.

Authors:  A U Haque; P Hudson; G Wood; N J Lindsey
Journal:  Jpn J Surg       Date:  1984-09

2.  Response of renal allograft recipients to pneumococcal vaccine.

Authors:  H Silberman; G D Overturf; R J Field; J Butler; T V Berne; R Witt
Journal:  Ann Surg       Date:  1980-08       Impact factor: 12.969

3.  Risk factors for pneumonia among patients with Parkinson's disease: a Taiwan nationwide population-based study.

Authors:  Yang-Pei Chang; Chih-Jen Yang; Kai-Fang Hu; A-Ching Chao; Yu-Han Chang; Kun-Pin Hsieh; Jui-Hsiu Tsai; Pei-Shan Ho; Shen-Yang Lim
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-27       Impact factor: 2.570

4.  A patient with a rapidly lethal pneumonia after a visit to a touristic area in rural Leon (Spain).

Authors:  M Valerio; F López-Medrano; I Regalado-Artamendi; P Muñoz; J M Aguado; E Bouza
Journal:  Rev Esp Quimioter       Date:  2018-06-28       Impact factor: 1.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.